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To the Editor, 
We thank Knight and colleagues1 for their interest in our recent meta-analysis on immune 
modulating nutrition (IMN) in patients undergoing surgery for gastrointestinal cancer.2 
While we appreciate their comments, we would like to clarify our methodology and 
interpretation. 
We included all participants in randomized clinical trials (RCTs) undergoing surgery for 
gastrointestinal cancer and receiving preoperative IMN for at least 3-days preoperatively. 
Hence, there were participants with and without malnutrition. However, as malnutrition 
may be present to a varying degree in at least 40% of patients undergoing cancer surgery, 
this mixed population of well-nourished and malnourished participants in the meta-analysis 
is representative of what would be observed in everyday clinical practice. Although the 
reduction in infective complications and length of stay was greatest in the study that 
included only malnourished participants,3 this benefit was still present in some studies that 
included less than 10% of malnourished participants.4-6 We, therefore, hypothesize that 
whilst IMN is beneficial in reducing infective complications in all patients undergoing surgery 
for gastrointestinal cancer, it is potentially more beneficial to those who are malnourished. 
Hence, we disagree with the assertion that this mixed population of participants, who met 
the inclusion criteria of each of the individual studies, were a “highly selected patient 
group”.1  
Not all the individual studies had defined their infective complications using established 
tools such as the Centre for Disease Control and Prevention guidelines7 or the Veterans 
Administration definitions.8 Additionally, not all studies had defined what regimens were 
used for perioperative antibiotic prophylaxis or antiseptic preparation. We, therefore, had 
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to assume that in each individual study, patients in the intervention and control arms would 
have been treated similarly. We also had to accept the possibility of clinical and statistical 
heterogeneity due to the potential variability in practices. Infective complications in each 
individual study did not only refer to surgical site infections as interpreted by Knight and 
colleagues.1 Infective complications included surgical site infections, deep wound infections, 
chest infections, intra-abdominal infections and urinary tract infections – all of which are 
possible complications that can occur after major surgery for gastrointestinal cancer. 
However, to account for the possibility of clinical and statistical heterogeneity between 
studies, we adopted the random effects model and for this particular outcome found 
heterogeneity to be low. 
We limited our searches to the Embase, Medline and Cochrane databases, and also 
undertook hand searches of the bibliographies of the studies that met the inclusion criteria. 
No studies were identified from low and middle income countries (LMIC) specifically. 
Following the comment from Knight and colleagues,1 we have searched the World Health 
Organisation Global Index Medicus database and have found no additional studies from 
LMIC evaluating the preoperative use of IMN in patients undergoing surgery for 
gastrointestinal cancer. We have also explored other published systematic reviews that 
have evaluated this question in other settings and in other surgical specialties and have not 
been able to identify any study from LMIC. There is clearly an information gap with regards 
to data on preoperative IMN in in patients undergoing surgery for gastrointestinal surgery in 
LMIC and teams with expertise in Global Surgery may wish to bridge this gap.  
Whilst the impact of IMN on patients with malnutrition and advanced cancer might be 
predicted to be higher, these patients have not been studied separately so we cannot 
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comment specifically. However, patients with advanced stage disease, cachexia and 
significant comorbidity are less likely to undergo resectional surgery for cancer, and so 
would not have met the inclusion criteria for the individual studies. Additionally, it would 
have been ethically difficult to randomize participants with cachexia, as they often require 
preoperative artificial nutrition, and in such cases clinical equipoise would not have been 
reached. If cachectic or severely malnourished patients cannot be recruited into trials in 
which they could be randomized to a placebo or no supplements at all, then the only 
mechanism of establishing benefit is to study patients with varying degrees of malnutrition 
or no malnutrition at all. And, if as was found in this case, benefit is identified, it is possible 
that the benefit may be extrapolated to cachectic patients. Knight and colleagues1 
themselves suggest that the impact of IMN on infectious complications is likely to be 
underestimated in our meta-analysis due to inclusion of well-nourished patients. However, 
we would argue that this makes it more generalizable, because if IMN has a positive impact 
in well-nourished participants, then it would be expected to be even more beneficial in 
malnourished ones. 
There are two suggestions that we hope are explored in the near future. First, a three arm 
trial comparing IMN with an isocaloric, isonitrogenous supplement and with a placebo in the 
same setting, with stricter definitions of infectious complications and surgical site infections 
in the current era of enhanced recovery protocols, should be undertaken to define the 
impact of IMN over and above a non-immune supplemented diet in patients having surgery 
for gastrointestinal cancer. Secondly, given the paucity of data from LMIC, where, as 
suggested, patients are more likely to be malnourished, it would be interesting to explore 
the effects of IMN in this setting.   
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